These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 3327939)

  • 1. Surfactant substitution in the newborn by application of artificial surfactant.
    Morley CJ
    J Perinat Med; 1987; 15(5):469-78. PubMed ID: 3327939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dry artificial lung surfactant and its effect on very premature babies.
    Morley CJ; Bangham AD; Miller N; Davis JA
    Lancet; 1981 Jan; 1(8211):64-8. PubMed ID: 6109119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of artificial surfactant (ALEC) in the prophylaxis of neonatal respiratory distress syndrome.
    Morley CJ
    Eur Respir J Suppl; 1989 Mar; 3():81s-86s. PubMed ID: 2663001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of artificial surfactant (ALEC) given at birth to babies from 23 to 34 weeks gestation.
    Morley CJ; Greenough A; Miller NG; Bangham AD; Pool J; Wood S; South M; Davis JA; Vyas H
    Early Hum Dev; 1988 May; 17(1):41-54. PubMed ID: 3061771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic treatment of premature babies with artificial surfactant (ALEC).
    Morley CJ
    Dev Pharmacol Ther; 1989; 13(2-4):182-3. PubMed ID: 2612300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neonatal respiratory distress syndrome and surfactant therapy; a brief review.
    Robertson B
    Eur Respir J Suppl; 1989 Mar; 3():73s-76s. PubMed ID: 2662999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants.
    Soll RF; Morley CJ
    Cochrane Database Syst Rev; 2001; (2):CD000510. PubMed ID: 11405966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled trial of artificial surfactant to prevent respiratory distress syndrome.
    Halliday HL; McClure G; Reid MM; Lappin TR; Meban C; Thomas PS
    Lancet; 1984 Mar; 1(8375):476-8. PubMed ID: 6142208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Respiratory compliance in premature babies treated with artificial surfactant (ALEC).
    Morley CJ; Greenough A
    Arch Dis Child; 1991 Apr; 66(4):467-71. PubMed ID: 2031602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants.
    Rojas-Reyes MX; Morley CJ; Soll R
    Cochrane Database Syst Rev; 2012 Mar; (3):CD000510. PubMed ID: 22419276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of exogenous surfactant on total respiratory system compliance.
    Milner AD; Vyas H; Hopkin IE
    Arch Dis Child; 1984 Apr; 59(4):369-71. PubMed ID: 6372707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome.
    Hudak ML; Martin DJ; Egan EA; Matteson EJ; Cummings NJ; Jung AL; Kimberlin LV; Auten RL; Rosenberg AA; Asselin JM; Belcastro MR; Donohue PK; Hamm CR; Jansen RD; Brody AS; Riddlesberger MM; Montgomery P
    Pediatrics; 1997 Jul; 100(1):39-50. PubMed ID: 9200358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early surfactant administration with brief ventilation vs selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome.
    Stevens TP; Blennow M; Soll RF
    Cochrane Database Syst Rev; 2004; (3):CD003063. PubMed ID: 15266470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of surfactant in the prevention and treatment of neonatal respiratory distress syndrome.
    Reynolds MS; Wallander KA
    Clin Pharm; 1989 Aug; 8(8):559-76. PubMed ID: 2670398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, placebo-controlled trial of human surfactant given at birth versus rescue administration in very low birth weight infants with lung immaturity.
    Merritt TA; Hallman M; Berry C; Pohjavuori M; Edwards DK; Jaaskelainen J; Grafe MR; Vaucher Y; Wozniak P; Heldt G
    J Pediatr; 1991 Apr; 118(4 Pt 1):581-94. PubMed ID: 2007937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of surfactant for prophylaxis versus rescue treatment of respiratory distress syndrome: experience from an Italian-Bulgarian trial.
    Bevilacqua G; Chernev T; Parmigiani S; Iarakova N; Gaioni L; Volante E; Gambini L; Bussolati G
    Acta Biomed Ateneo Parmense; 1997; 68 Suppl 1():47-54. PubMed ID: 10021717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary mechanics in ventilated preterm infants with respiratory distress syndrome after exogenous surfactant administration: a comparison between two surfactant preparations.
    Choukroun ML; Llanas B; Apere H; Fayon M; Galperine RI; Guenard H; Demarquez JL
    Pediatr Pulmonol; 1994 Nov; 18(5):273-8. PubMed ID: 7898964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ten centre trial of artificial surfactant (artificial lung expanding compound) in very premature babies. Ten Centre Study Group.
    Br Med J (Clin Res Ed); 1987 Apr; 294(6578):991-6. PubMed ID: 2890398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome.
    Fujii A; Allen R; Doros G; O'Brien S
    J Perinatol; 2010 Oct; 30(10):671-6. PubMed ID: 20336077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic treatment of very premature infants with human surfactant.
    Merritt TA; Hallman M; Bloom BT; Berry C; Benirschke K; Sahn D; Key T; Edwards D; Jarvenpaa AL; Pohjavuori M
    N Engl J Med; 1986 Sep; 315(13):785-90. PubMed ID: 3528853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.